Home › Therapeutic areas › Oncology › Small Cell Lung Cancer
Small Cell Lung Cancer (8 companies)
Companies with an active program in Small Cell Lung Cancer.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACRV | Acrivon Therapeutics | GI/HepatologyOncology Rare | 1 | Phase 2 | $69.0M | 9 |
| AKTS | Aktis Oncology | Oncology | 1 | Phase 1 | $880M | 10 |
| ALLO | Allogene Therapeutics | ImmunologyOncology Rare | 1 | Phase 2 | $360M | 10 |
| CMPX | Compass Therapeutics | Oncology | 1 | Phase 2 | $137M | 15 |
| GNLX | Genelux | Oncology | 1 | Phase 3 | $88.7M | 3 |
| IDYA | IDEAYA Biosciences | Oncology | 2 | NDA Submitted | $3.02B | 14 |
| LEGN | Legend Biotech | Oncology Rare | 1 | Approved | $4.55B | 17 |
| ZYME | Zymeworks | OncologyRespiratory | 1 | Approved | $2.10B | 11 |
No companies match.